Year |
Citation |
Score |
2023 |
Riedinger CJ, Esnakula A, Haight PJ, Suarez AA, Chen W, Gillespie J, Villacres A, Chassen A, Cohn DE, Goodfellow PJ, Cosgrove CM. Characterization of mismatch-repair (MMR)/microsatellite instability (MSI)-discordant endometrial cancers. Cancer. PMID 37751191 DOI: 10.1002/cncr.35030 |
0.308 |
|
2021 |
Hampel H, Pearlman R, de la Chapelle A, Pritchard CC, Zhao W, Jones D, Yilmaz A, Chen W, Frankel WL, Suarez AA, Cosgrove C, Backes F, Copeland L, Fowler J, O'Malley D, ... ... Goodfellow P, et al. Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients. Gynecologic Oncology. 160: 161-168. PMID 33393477 DOI: 10.1016/j.ygyno.2020.10.012 |
0.319 |
|
2020 |
Koivisto CS, Parrish M, Bonala SB, Ngoi S, Torres A, Gallagher J, Sanchez-Hodge R, Zeinner V, Nahhas GJ, Liu B, Cohn DE, Backes FJ, Goodfellow PJ, Chamberlin HM, Leone G. Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinoma. Neoplasia (New York, N.Y.). 22: 484-496. PMID 32818842 DOI: 10.1016/J.Neo.2020.07.003 |
0.421 |
|
2020 |
Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902960. PMID 31986064 DOI: 10.1200/Jco.19.02960 |
0.437 |
|
2020 |
Koivisto CS, Melodie P, Santosh B, Ngoi S, Nahhas GJ, Liu B, Torres A, Gallagher J, Snchez-Hodge R, Zeinner V, Cohn D, Backes F, Goodfellow P, Chamberlin H, Leone G. Abstract 627: Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinoma Cancer Research. 80: 627-627. DOI: 10.1158/1538-7445.Am2020-627 |
0.444 |
|
2019 |
Moyer CL, Ivanovich J, Gillespie JL, Doberstein R, Radke MR, Richardson ME, Kaufmann SH, Swisher EM, Goodfellow PJ. Rare BRIP1 missense alleles confer risk for ovarian and breast cancer. Cancer Research. PMID 31822495 DOI: 10.1158/0008-5472.Can-19-1991 |
0.428 |
|
2019 |
Aryal NK, Pant V, Wasylishen AR, Rimel B, Baseler L, El-Naggar AK, Mutch DG, Goodfellow PJ, Arur S, Lozano G. Dicer1 phospho-mimetic promotes tumor progression and dissemination. Cancer Research. PMID 30914430 DOI: 10.1158/0008-5472.Can-18-2460 |
0.471 |
|
2019 |
Brooks RA, Tritchler DS, Darcy KM, Lankes HA, Salani R, Sperduto P, Guntupalli S, DiSilvestro P, Kesterson J, Olawaiye AB, Moxley K, Waggoner S, Santin A, Rader JS, Kizer NT, ... ... Goodfellow PJ, et al. GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study. Gynecologic Oncology. PMID 30827726 DOI: 10.1016/J.Ygyno.2019.02.028 |
0.357 |
|
2019 |
Rush CM, Goodfellow PJ. Diverse mutational signatures in endometrial cancer: implications for tumor etiology and evolution. Gynecologic Oncology. 152: 1-2. PMID 30611321 DOI: 10.1016/J.Ygyno.2018.12.004 |
0.486 |
|
2018 |
Backes FJ, Haag J, Cosgrove CM, Suarez A, Cohn DE, Goodfellow PJ. Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker. Cancer. PMID 30561762 DOI: 10.1097/Ogx.0000000000000668 |
0.336 |
|
2018 |
Polusani SR, Huang YW, Huang G, Chen CW, Wang CM, Lin LL, Osmulski P, Lucio ND, Liu L, Hsu YT, Zhou Y, Lin CL, Aguilera-Barrantes I, Valente PT, Kost ER, ... ... Goodfellow PJ, et al. Adipokines Deregulate Cellular Communication via Epigenetic Repression of Gap Junction Loci in Obese Endometrial Cancer. Cancer Research. PMID 30389702 DOI: 10.1158/0008-5472.Can-18-1615 |
0.424 |
|
2018 |
Neff R, Rush CM, Smith B, Backes FJ, Cohn DE, Goodfellow PJ. Functional characterization of recurrent FOXA2 mutations seen in endometrial cancers. International Journal of Cancer. PMID 30091462 DOI: 10.1002/Ijc.31784 |
0.486 |
|
2018 |
Arend RC, Jones BA, Martinez A, Goodfellow P. Endometrial cancer: Molecular markers and management of advanced stage disease. Gynecologic Oncology. PMID 29843906 DOI: 10.1016/J.Ygyno.2018.05.015 |
0.416 |
|
2018 |
Hampel H, Pearlman R, Beightol M, Zhao W, Jones D, Frankel WL, Goodfellow PJ, Yilmaz A, Miller K, Bacher J, Jacobson A, Paskett E, Shields PG, Goldberg RM, de la Chapelle A, et al. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer. Jama Oncology. PMID 29596542 DOI: 10.1001/Jamaoncol.2018.0104 |
0.395 |
|
2018 |
Saini U, Suarez AA, Naidu S, Wallbillich JJ, Bixel K, Wanner R, Bice J, Kladney RD, Lester J, Karlan BY, Goodfellow PJ, Cohn DE, Selvendiran K. STAT3/PIAS3 levels serve as "early signature" genes in the development of high-grade serous carcinoma from the fallopian tube. Cancer Research. PMID 29339537 DOI: 10.1158/0008-5472.Can-17-1671 |
0.4 |
|
2018 |
Vetter M, Backes F, Cosgrove C, Gillespie J, Salani R, O'Malley D, Fowler J, Cohn D, Goodfellow P. Adherence to NCCN guidelines for the treatment of endometrial cancer: Will mismatch repair status matter? Gynecologic Oncology. 149: 185-186. DOI: 10.1016/J.Ygyno.2018.04.422 |
0.348 |
|
2018 |
Haag J, Cosgrove C, Cohn D, Suarez A, Goodfellow P, Backes F. MMR deficiency identifies patients with high intermediate risk (HIR) endometrial cancer at highest risk of recurrence: A prognostic and possible predictive biomarker for HIR endometrial cancer Gynecologic Oncology. 149: 180. DOI: 10.1016/J.Ygyno.2018.04.409 |
0.376 |
|
2017 |
Walker CJ, Rush CM, Dama P, O'Hern MJ, Cosgrove CM, Gillespie JL, Zingarelli RA, Smith B, Stein ME, Mutch DG, Shakya R, Chang CW, Selvendiran K, Song JW, Cohn DE, ... Goodfellow PJ, et al. MAX Mutations in Endometrial Cancer: Clinicopathologic Associations and Recurrent MAX p.His28Arg Functional Characterization. Journal of the National Cancer Institute. PMID 29155953 DOI: 10.1093/Jnci/Djx238 |
0.445 |
|
2017 |
MacKay HJ, Levine DA, Bae-Jump VL, Bell DW, McAlpine JN, Santin A, Fleming GF, Mutch DG, Nephew KP, Wentzensen N, Goodfellow PJ, Dorigo O, Nijman HW, Broaddus R, Kohn EC. Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. Oncotarget. 8: 84579-84594. PMID 29137450 DOI: 10.18632/Oncotarget.19961 |
0.4 |
|
2017 |
Cosgrove CM, Tritchler DL, Cohn DE, Mutch DG, Rush CM, Lankes HA, Creasman WT, Miller DS, Ramirez NC, Geller MA, Powell MA, Backes FJ, Landrum LM, Timmers C, Suarez AA, ... ... Goodfellow PJ, et al. An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. Gynecologic Oncology. PMID 29132872 DOI: 10.1016/J.Ygyno.2017.10.037 |
0.356 |
|
2017 |
Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, Lindström S, Hui S, Lemaçon A, Soucy P, Dennis J, Jiang X, Rostamianfar A, Finucane H, Bolla MK, McGuffog L, ... ... Goodfellow P, et al. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics. PMID 29058716 DOI: 10.1038/Ng.3785 |
0.359 |
|
2017 |
Walker CJ, O'Hern MJ, Serna VA, Kurita T, Miranda MA, Sapp CE, Mutch DG, Cohn DE, Goodfellow PJ. Novel SOX17 frameshift mutations in endometrial cancer are functionally distinct from recurrent missense mutations. Oncotarget. 8: 68758-68768. PMID 28978154 DOI: 10.18632/Oncotarget.20213 |
0.418 |
|
2017 |
Cosgrove CM, Cohn DE, Goodfellow PJ. Primum non nocere: Are we ready for POLE testing in endometrial cancer? Gynecologic Oncology. PMID 28947175 DOI: 10.1016/J.Ygyno.2017.09.015 |
0.369 |
|
2017 |
Le Gallo M, Rudd ML, Urick ME, Hansen NF, Merino MJ, Mutch DG, Goodfellow PJ, Mullikin JC, Bell DW. The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. Cancer. PMID 28940304 DOI: 10.1002/Cncr.30971 |
0.461 |
|
2017 |
Cosgrove CM, Cohn DE, Hampel H, Frankel WL, Jones D, McElroy JP, Suarez AA, Zhao W, Chen W, Salani R, Copeland LJ, O'Malley DM, Fowler JM, Yilmaz A, Chassen AS, ... ... Goodfellow PJ, et al. Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival. Gynecologic Oncology. PMID 28709704 DOI: 10.1016/J.Ygyno.2017.07.003 |
0.371 |
|
2017 |
Le Gallo M, Rudd ML, Urick ME, Hansen NF, Zhang S, Lozy F, Sgroi DC, Vidal Bel A, Matias-Guiu X, Broaddus RR, Lu KH, Levine DA, Mutch DG, Goodfellow PJ, et al. Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing. Cancer. PMID 28485815 DOI: 10.1002/Cncr.30745 |
0.471 |
|
2017 |
Jeske YW, Ali S, Byron SA, Gao F, Mannel RS, Ghebre RG, DiSilvestro PA, Lele SB, Pearl ML, Schmidt AP, Lankes HA, Ramirez NC, Rasty G, Powell M, Goodfellow PJ, et al. FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. PMID 28314589 DOI: 10.1016/J.Ygyno.2017.02.031 |
0.398 |
|
2017 |
Trimarchi MP, Yan P, Groden J, Bundschuh R, Goodfellow PJ. Identification of endometrial cancer methylation features using combined methylation analysis methods. Plos One. 12: e0173242. PMID 28278225 DOI: 10.1371/Journal.Pone.0173242 |
0.366 |
|
2017 |
Neff R, Rush CM, Walker CJ, Backes FJ, Cohn DE, Goodfellow PJ. Functional characterization of recurrent FOXA2 mutations in endometrial cancer Gynecologic Oncology. 145: 109. DOI: 10.1016/J.Ygyno.2017.03.258 |
0.434 |
|
2016 |
Pearlman R, Frankel WL, Swanson B, Zhao W, Yilmaz A, Miller K, Bacher J, Bigley C, Nelsen L, Goodfellow PJ, Goldberg RM, Paskett E, Shields PG, Freudenheim JL, Stanich PP, et al. Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer. Jama Oncology. PMID 27978560 DOI: 10.1001/Jamaoncol.2016.5194 |
0.44 |
|
2016 |
Smith B, Neff R, Cohn DE, Backes FJ, Suares AA, Mutch DG, Rush CM, Walker CJ, Goodfellow PJ. The mutational spectrum of FOXA2 in endometrioid endometrial cancer points to a tumor suppressor role. Gynecologic Oncology. PMID 27538367 DOI: 10.1016/J.Ygyno.2016.08.237 |
0.477 |
|
2016 |
Walker CJ, Miranda MA, Matthew J O, Blachly JS, Moyer CL, Ivanovich J, Krol0l KW, Eisfeld AK, Sapp CE, Mutch DG, Cohn DE, Bundschuh R, Goodfellow PJ. MonoSeq Variant Caller Reveals Novel Mononucleotide Run Indel Mutations in Tumors with Defective DNA Mismatch Repair. Human Mutation. PMID 27346418 DOI: 10.1002/Humu.23036 |
0.446 |
|
2016 |
McMeekin DS, Tritchler DL, Cohn DE, Mutch DG, Lankes HA, Geller MA, Powell MA, Backes FJ, Landrum LM, Zaino R, Broaddus RD, Ramirez N, Gao F, Ali S, Darcy KM, ... ... Goodfellow PJ, et al. Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27325856 DOI: 10.1200/Jco.2016.67.8722 |
0.4 |
|
2016 |
Cohen SA, Turner EH, Beightol MB, Jacobson A, Gooley TA, Salipante SJ, Haraldsdottir S, Smith C, Scroggins S, Tait JF, Grady WM, Lin EH, Cohn DE, Goodfellow PJ, Arnold MW, et al. Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors with 2 or More Somatic Mutations in Mismatch Repair Genes. Gastroenterology. PMID 27302833 DOI: 10.1053/J.Gastro.2016.06.004 |
0.431 |
|
2016 |
Saini U, Naidu S, ElNaggar AC, Bid HK, Wallbillich JJ, Bixel K, Bolyard C, Suarez AA, Kaur B, Kuppusamy P, Hays J, Goodfellow PJ, Cohn DE, Selvendiran K. Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target. Oncogene. PMID 27292260 DOI: 10.1038/Onc.2016.197 |
0.468 |
|
2016 |
Backes FJ, Walker CJ, Goodfellow PJ, Hade EM, Agarwal G, Mutch D, Cohn DE, Suarez AA. Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer. Gynecologic Oncology. 141: 312-7. PMID 26957478 DOI: 10.1016/J.Ygyno.2016.03.006 |
0.337 |
|
2016 |
Billingsley CC, Cohn DE, Mutch DG, Hade EM, Goodfellow PJ. Prognostic Significance of POLE Exonuclease Domain Mutations in High-Grade Endometrioid Endometrial Cancer on Survival and Recurrence: A Subanalysis. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 26: 933-8. PMID 26937754 DOI: 10.1097/Igc.0000000000000681 |
0.398 |
|
2016 |
Sunkel B, Wu D, Chen Z, Wang CM, Liu X, Ye Z, Horning AM, Liu J, Mahalingam D, Lopez-Nicora H, Lin CL, Goodfellow PJ, Clinton SK, Jin VX, Chen CL, et al. Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence. Nucleic Acids Research. PMID 26743006 DOI: 10.1093/Nar/Gkv1528 |
0.395 |
|
2016 |
Saini U, Wallbillich J, Riley MR, Fowler JM, Wanner R, Lester J, Karlan B, Goodfellow P, Suarez A, Cohn D, Selvendiran K. Abstract LB-130: STAT3/PIAS3 as “early signature” gene pathways in the development of ovarian high grade serous carcinoma from the fallopian tube Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-130 |
0.473 |
|
2016 |
Saini U, Naidu S, ElNaggar AC, Bid HK, Wallbillich J, Wanner R, Bixel K, Riley M, Bolyard C, Suarez AA, Kaur B, Kuppusamy P, Hays J, Goodfellow P, Cohn DE, et al. Abstract LB-036: Elevated STAT3 expression in ovarian tumor ascites regulates invasion and metastasis: a promising therapeutic target Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-036 |
0.465 |
|
2016 |
Walker CJ, Rush C, Dama P, Stein M, Shakya R, O’Hern M, Mutch DG, Cohn DE, Goodfellow PJ. Abstract 2002: MAX mutations in endometrial cancer are associated with poor patient outcome, altered E-box binding, and increased tumor vascularity Cancer Research. 76: 2002-2002. DOI: 10.1158/1538-7445.Am2016-2002 |
0.487 |
|
2016 |
Neff R, Smith B, Cohn D, Backes F, Mutch D, Goodfellow P. Epigenetic regulation of FOXA2 in endometrial cancer Gynecologic Oncology. 141: 193-194. DOI: 10.1016/J.Ygyno.2016.04.499 |
0.419 |
|
2016 |
Dorayappan K, Wallbillich J, Saini U, Bixel K, Riley M, Zingarelli R, Wanner R, Goodfellow P, Cohn D, Karuppaiyah S. Hypoxia-facilitated exosomal release from ovarian cancer cells is regulated by STAT3 and is associated with increased metastatic tumor burden Gynecologic Oncology. 141: 66. DOI: 10.1016/J.Ygyno.2016.04.193 |
0.443 |
|
2016 |
Saini U, Bixel K, Wallbillich J, Riley M, Fowler J, Wanner R, Lester J, Karlan B, Goodfellow P, Suarez A, Cohn D, Karuppaiyah S. STAT3/PIAS3 as 'early signature' gene pathways in the development of ovarian high-grade serous carcinoma from the fallopian tube Gynecologic Oncology. 141: 56. DOI: 10.1016/J.Ygyno.2016.04.167 |
0.324 |
|
2015 |
Brenneman M, Field A, Yang J, Williams G, Doros L, Rossi C, Schultz KA, Rosenberg A, Ivanovich J, Turner J, Gordish-Dressman H, Stewart D, Yu W, Harris A, Schoettler P, ... Goodfellow P, et al. Temporal order of RNase IIIb and loss-of-function mutations during development determines phenotype in DICER1 syndrome: a unique variant of the two-hit tumor suppression model. F1000research. 4: 214. PMID 26925222 DOI: 10.12688/F1000Research.6746.2 |
0.396 |
|
2015 |
Lu C, Xie M, Wendl MC, Wang J, McLellan MD, Leiserson MD, Huang KL, Wyczalkowski MA, Jayasinghe R, Banerjee T, Ning J, Tripathi P, Zhang Q, Niu B, Ye K, ... ... Goodfellow PJ, et al. Patterns and functional implications of rare germline variants across 12 cancer types. Nature Communications. 6: 10086. PMID 26689913 DOI: 10.1038/Ncomms10086 |
0.465 |
|
2015 |
Rocconi RP, Lankes HA, Brady WE, Goodfellow PJ, Ramirez NC, Alvarez RD, Creasman W, Fernández JR. The role of racial genetic admixture with endometrial cancer outcomes: An NRG oncology/gynecologic oncology group study. Gynecologic Oncology. PMID 26603970 DOI: 10.1016/J.Ygyno.2015.11.018 |
0.323 |
|
2015 |
Goodfellow PJ, Billingsley CC, Lankes HA, Ali S, Cohn DE, Broaddus RJ, Ramirez N, Pritchard CC, Hampel H, Chassen AS, Simmons LV, Schmidt AP, Gao F, Brinton LA, Backes F, et al. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26552419 DOI: 10.1200/Jco.2015.63.9518 |
0.402 |
|
2015 |
Walker CJ, Miranda MA, O'Hern MJ, McElroy JP, Coombes KR, Bundschuh R, Cohn DE, Mutch DG, Goodfellow PJ. Patterns of CTCF and ZFHX3 Mutation and Associated Outcomes in Endometrial Cancer. Journal of the National Cancer Institute. 107. PMID 26330387 DOI: 10.1093/Jnci/Djv249 |
0.483 |
|
2015 |
Caserta E, Egriboz O, Wang H, Martin C, Koivisto C, Pecót T, Kladney RD, Shen C, Shim KS, Pham T, Karikomi MK, Mauntel MJ, Majumder S, Cuitino MC, Tang X, ... ... Goodfellow P, et al. Noncatalytic PTEN missense mutation predisposes to organ-selective cancer development in vivo. Genes & Development. 29: 1707-20. PMID 26302789 DOI: 10.1101/Gad.262568.115 |
0.441 |
|
2015 |
Zighelboim I, Ali S, Lankes HA, Backes F, Moore K, Mutch D, Robison K, Behbakht K, Waggoner S, Ghebre RG, Pearl M, Ramirez NC, Goodfellow P. Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. 138: 614-9. PMID 26144601 DOI: 10.1016/J.Ygyno.2015.06.038 |
0.439 |
|
2015 |
Lin Y, Lin S, Baxter MD, Lin L, Kennedy SM, Zhang Z, Goodfellow PJ, Chapman WC, Davidson NO. Novel APC promoter and exon 1B deletion and allelic silencing in three mutation-negative classic familial adenomatous polyposis families. Genome Medicine. 7: 42. PMID 25941542 DOI: 10.1186/S13073-015-0148-0 |
0.367 |
|
2015 |
Kaphingst KA, Ivanovich J, Biesecker BB, Dresser R, Seo J, Dressler LG, Goodfellow PJ, Goodman MS. Preferences for return of incidental findings from genome sequencing among women diagnosed with breast cancer at a young age. Clinical Genetics. PMID 25871653 DOI: 10.1111/Cge.12597 |
0.315 |
|
2015 |
Billingsley CC, Cohn DE, Mutch DG, Stephens JA, Suarez AA, Goodfellow PJ. Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing. Cancer. 121: 386-94. PMID 25224212 DOI: 10.1002/Cncr.29046 |
0.454 |
|
2015 |
Shiovitz S, Turner E, Beightol M, Jacobson A, Gooley T, Salipante SJ, Haraldsdottir S, Tait JF, Grady WM, Lin EH, De La Chapelle A, Cohn DE, Goodfellow PJ, Arnold M, Hampel H, et al. PIK3CA mutations in colorectal and endometrial cancer with double somatic mismatch repair mutations compared to Lynch syndrome. Journal of Clinical Oncology. 33: 3550-3550. DOI: 10.1200/Jco.2015.33.15_Suppl.3550 |
0.459 |
|
2015 |
Walker CJ, Miranda MA, O'Hern M, Coombes K, Bundschuh R, Mutch DG, Goodfellow PJ. Abstract 5300: Loss of function of two closely linked tumor suppressors contributes to biologic aggressiveness in endometrial cancers: Co-mutation of CTCF and ZFHX3 Cancer Research. 75: 5300-5300. DOI: 10.1158/1538-7445.Am2015-5300 |
0.479 |
|
2015 |
Naidu S, Saini U, ElNaggar AC, Bid HK, Wanner R, Bixel K, Suarez AA, Bolyard C, Kaur B, Goodfellow PJ, Kuppusamy P, Cohn D, Selvendiran K. Abstract 1720: HO-3867, a selective inhibitor of stat3, suppress ovarian tumor growth and metastasis in human tissue culture and in an orthotopic mouse model Cancer Research. 75: 1720-1720. DOI: 10.1158/1538-7445.Am2015-1720 |
0.324 |
|
2015 |
Billingsley C, Hade E, Cohn D, Mutch D, Goodfellow P. Abstract 2: Prognostic significance of POLE exonuclease domain mutations in high grade endometrioid endometrial cancer on survival and recurrence Gynecologic Oncology. 137: 591-592. DOI: 10.1016/J.Ygyno.2015.03.019 |
0.386 |
|
2015 |
Smith B, Cohn D, Mutch D, Miranda M, Walker C, Goodfellow P. Unveiling novel mutations in the DNA-binding domain of FOXA2 in endometrioid endometrial cancers Gynecologic Oncology. 137: 205. DOI: 10.1016/J.Ygyno.2015.01.516 |
0.386 |
|
2015 |
Naidu S, Saini U, ElNaggar A, Rath K, Hemant B, Lata P, Wanner R, Sudhakar M, Suarez A, Hays J, Goodfellow P, Cohn D, Karuppaiyah S. Suppression of ovarian cancer growth and metastasis with HO-3867, a STAT3 inhibitor, in human tissue culture and in an orthotopic mouse model Gynecologic Oncology. 137: 202. DOI: 10.1016/J.Ygyno.2015.01.507 |
0.352 |
|
2015 |
Mutch D, Powell M, Schmidt A, Broaddus R, Ramirez N, Tritchler D, Ali S, Lankes H, O'Malley D, Goodfellow P. Clinicopathologic features associated with defective DNA mismatch repair (MMR): A GOG 0210 cohort study of 1041 endometrioid endometrial cancer cases Gynecologic Oncology. 137: 20-21. DOI: 10.1016/J.Ygyno.2015.01.047 |
0.351 |
|
2015 |
Billingsley C, Cohn D, Mutch D, Broaddus R, Ramirez N, Lankes H, Ali S, Backes F, Landrum L, Goodfellow P. Clinical implications for MSI, MLH1 methylation analysis and IHC in Lynch screening for endometrial cancer patients: An analysis of 940 endometrioid endometrial cancer cases from the GOG 0210 study Gynecologic Oncology. 137: 4-5. DOI: 10.1016/J.Ygyno.2015.01.008 |
0.404 |
|
2014 |
Zhang B, Xing X, Li J, Lowdon RF, Zhou Y, Lin N, Zhang B, Sundaram V, Chiappinelli KB, Hagemann IS, Mutch DG, Goodfellow PJ, Wang T. Comparative DNA methylome analysis of endometrial carcinoma reveals complex and distinct deregulation of cancer promoters and enhancers. Bmc Genomics. 15: 868. PMID 25286960 DOI: 10.1186/1471-2164-15-868 |
0.697 |
|
2014 |
Tierney BJ, McCann GA, Naidu S, Rath KS, Saini U, Wanner R, Kuppusamy P, Suarez A, Goodfellow PJ, Cohn DE, Selvendiran K. Aberrantly activated pSTAT3-Ser727 in human endometrial cancer is suppressed by HO-3867, a novel STAT3 inhibitor. Gynecologic Oncology. 135: 133-41. PMID 25038288 DOI: 10.1016/J.Ygyno.2014.07.087 |
0.428 |
|
2014 |
Huang YW, Kuo CT, Chen JH, Goodfellow PJ, Huang TH, Rader JS, Uyar DS. Hypermethylation of miR-203 in endometrial carcinomas. Gynecologic Oncology. 133: 340-5. PMID 24530564 DOI: 10.1016/J.Ygyno.2014.02.009 |
0.316 |
|
2014 |
Kanchi KL, Johnson KJ, Lu C, McLellan MD, Leiserson MD, Wendl MC, Zhang Q, Koboldt DC, Xie M, Kandoth C, McMichael JF, Wyczalkowski MA, Larson DE, Schmidt HK, Miller CA, ... ... Goodfellow PJ, et al. Integrated analysis of germline and somatic variants in ovarian cancer. Nature Communications. 5: 3156. PMID 24448499 DOI: 10.1038/Ncomms4156 |
0.444 |
|
2014 |
Joehlin-Price AS, Perrino CM, Stephens J, Backes FJ, Goodfellow PJ, Cohn DE, Suarez AA. Mismatch repair protein expression in 1049 endometrial carcinomas, associations with body mass index, and other clinicopathologic variables. Gynecologic Oncology. 133: 43-7. PMID 24444820 DOI: 10.1016/J.Ygyno.2014.01.017 |
0.301 |
|
2014 |
Purrington KS, Slager S, Eccles D, Yannoukakos D, Fasching PA, Miron P, Carpenter J, Chang-Claude J, Martin NG, Montgomery GW, Kristensen V, Anton-Culver H, Goodfellow P, Tapper WJ, Rafiq S, et al. Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis. 35: 1012-9. PMID 24325915 DOI: 10.1093/Carcin/Bgt404 |
0.35 |
|
2014 |
Zighelboim I, Mutch DG, Knapp A, Ding L, Xie M, Cohn DE, Goodfellow PJ. High Frequency Strand Slippage Mutations in CTCF in MSI-Positive Endometrial Cancers Human Mutation. 35: 63-65. PMID 24130125 DOI: 10.1002/Humu.22463 |
0.465 |
|
2014 |
McConechy MK, Ding J, Senz J, Yang W, Melnyk N, Tone AA, Prentice LM, Wiegand KC, McAlpine JN, Shah SP, Lee CH, Goodfellow PJ, Gilks CB, Huntsman DG. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles Modern Pathology. 27: 128-134. PMID 23765252 DOI: 10.1038/Modpathol.2013.107 |
0.385 |
|
2014 |
Purrington KS, Yannoukakos D, Carpenter J, Nevanlinna H, Cox A, Severi G, Ambrosone C, Toland AE, Godwin AK, Brauch H, Fasching PA, Miron P, Chang-Claude J, Martin NG, Montgomery GW, ... ... Goodfellow P, et al. Abstract 3266: Expression quantitative trait locus analysis of triple negative breast cancer Cancer Research. 74: 3266-3266. DOI: 10.1158/1538-7445.Am2014-3266 |
0.373 |
|
2014 |
Walker CJ, Miranda MA, Mutch DG, Goodfellow P. Abstract 1540: CCCTC-binding factor (CTCF) mutation in endometrioid endometrial carcinoma (EEC): Master epimutator contributing to biologic aggressiveness Cancer Research. 74: 1540-1540. DOI: 10.1158/1538-7445.Am2014-1540 |
0.517 |
|
2014 |
Hsu Y, Gu F, Huang Y, Liu J, Ruan J, Huang R, Wang C, Chen C, Jadhav RR, Wang Y, Jin VX, Lai H, Mutch DG, Goodfellow PJ, Thompson IM, et al. Abstract 1376: EpCAM-mediated hypomethylation of BMP and cell adhesion genes is associated with advanced endometrial cancer Cancer Research. 74: 1376-1376. DOI: 10.1158/1538-7445.Am2014-1376 |
0.495 |
|
2014 |
Billingsley C, Cohn D, Mutch D, Goodfellow P. Evaluation of incidence and prognostic significance of newly identified hotspot mutations in DNA polymerase epsilon (POLE) in endometrial cancer: Contextualizing findings from The Cancer Genome Atlas Research Network Gynecologic Oncology. 133: 4. DOI: 10.1016/J.Ygyno.2014.03.026 |
0.434 |
|
2013 |
Creutzberg CL, Kitchener HC, Birrer MJ, Landoni F, Lu KH, Powell M, Aghajanian C, Edmondson R, Goodfellow PJ, Quinn M, Salvesen HB, Thomas G. Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: taking endometrial cancer trials into the translational era. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 23: 1528-34. PMID 24257568 DOI: 10.1097/Igc.0B013E3182A26Edb |
0.353 |
|
2013 |
Hsu YT, Gu F, Huang YW, Liu J, Ruan J, Huang RL, Wang CM, Chen CL, Jadhav RR, Lai HC, Mutch DG, Goodfellow PJ, Thompson IM, Kirma NB, Huang TH. Promoter hypomethylation of EpCAM-regulated bone morphogenetic protein gene family in recurrent endometrial cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6272-85. PMID 24077349 DOI: 10.1158/1078-0432.Ccr-13-1734 |
0.411 |
|
2013 |
Yin Y, Kizer NT, Thaker PH, Chiappinelli KB, Trinkaus KM, Goodfellow PJ, Ma L. Glycogen synthase kinase 3β inhibition as a therapeutic approach in the treatment of endometrial cancer. International Journal of Molecular Sciences. 14: 16617-37. PMID 23941783 DOI: 10.1016/J.Ygyno.2011.12.352 |
0.7 |
|
2013 |
Gu F, Doderer MS, Huang YW, Roa JC, Goodfellow PJ, Kizer EL, Huang TH, Chen Y. CMS: a web-based system for visualization and analysis of genome-wide methylation data of human cancers. Plos One. 8: e60980. PMID 23630576 DOI: 10.1371/Journal.Pone.0060980 |
0.394 |
|
2013 |
Mach CM, Kim J, Soibam B, Creighton CJ, Hawkins SM, Zighelboim I, Goodfellow P, Gunaratne PH, Odunsi K, Salem PA, Anderson ML. Novel MicroRNAs regulating proliferation and apoptosis in uterine papillary serous carcinomas. Cancer Letters. 335: 314-22. PMID 23454583 DOI: 10.1016/J.Canlet.2013.02.043 |
0.348 |
|
2013 |
Novetsky AP, Thompson DM, Zighelboim I, Thaker PH, Powell MA, Mutch DG, Goodfellow PJ. Lithium chloride and inhibition of glycogen synthase kinase 3β as a potential therapy for serous ovarian cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 23: 361-6. PMID 23295942 DOI: 10.1097/Igc.0B013E31827Cfecb |
0.344 |
|
2013 |
Novetsky AP, Zighelboim I, Thompson DM, Powell MA, Mutch DG, Goodfellow PJ. Frequent mutations in the RPL22 gene and its clinical and functional implications. Gynecologic Oncology. 128: 470-4. PMID 23127973 DOI: 10.1016/J.Ygyno.2012.10.026 |
0.437 |
|
2013 |
Pennington KP, Walsh T, Lee M, Pennil C, Novetsky AP, Agnew KJ, Thornton A, Garcia R, Mutch D, King MC, Goodfellow P, Swisher EM. BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. Cancer. 119: 332-8. PMID 22811390 DOI: 10.1002/Cncr.27720 |
0.377 |
|
2013 |
Trimarchi MP, Yan PS, Huang K, Groden J, Bundschuh R, Goodfellow PJ. Abstract B41: Methylome profiling identifies unique patterns of DNA methylation in endometrial cancers Cancer Research. 73. DOI: 10.1158/1538-7445.Cec13-B41 |
0.419 |
|
2013 |
Rocconi R, Fernandez J, Brady W, Darcy K, Goodfellow P, Lankes H, Tritchler D, Ramirez N, Creasman W, Alvarez R. The role of racial genetic admixture with endometrial cancer outcomes: A Gynecologic Oncology Group study Gynecologic Oncology. 130: e168-e169. DOI: 10.1016/J.Ygyno.2013.04.466 |
0.334 |
|
2012 |
Pritchard CC, Smith C, Salipante SJ, Lee MK, Thornton AM, Nord AS, Gulden C, Kupfer SS, Swisher EM, Bennett RL, Novetsky AP, Jarvik GP, Olopade OI, Goodfellow PJ, King MC, et al. ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. The Journal of Molecular Diagnostics : Jmd. 14: 357-66. PMID 22658618 DOI: 10.1016/J.Jmoldx.2012.03.002 |
0.41 |
|
2012 |
McConechy MK, Ding J, Cheang MCU, Wiegand KC, Senz J, Tone AA, Yang W, Prentice LM, Tse K, Zeng T, McDonald H, Schmidt AP, Mutch DG, McAlpine JN, Hirst M, ... ... Goodfellow PJ, et al. Use of mutation profiles to refine the classification of endometrial carcinomas Journal of Pathology. 228: 20-30. PMID 22653804 DOI: 10.1002/Path.4056 |
0.374 |
|
2012 |
Byron SA, Gartside M, Powell MA, Wellens CL, Gao F, Mutch DG, Goodfellow PJ, Pollock PM. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. Plos One. 7: e30801. PMID 22383975 DOI: 10.1371/Journal.Pone.0030801 |
0.4 |
|
2012 |
Chiappinelli KB, Haynes BC, Brent MR, Goodfellow PJ. Reduced DICER1 elicits an interferon response in endometrial cancer cells. Molecular Cancer Research : McR. 10: 316-25. PMID 22252463 DOI: 10.1158/1541-7786.Mcr-11-0520 |
0.678 |
|
2012 |
Dewdney SB, Kizer NT, Andaya AA, Babb SA, Luo J, Mutch DG, Schmidt AP, Brinton LA, Broaddus RR, Ramirez NC, Huettner PC, McMeekin DS, Darcy K, Ali S, Judson PL, ... ... Goodfellow PJ, et al. Uterine serous carcinoma: increased familial risk for lynch-associated malignancies. Cancer Prevention Research (Philadelphia, Pa.). 5: 435-43. PMID 22246618 DOI: 10.1158/1940-6207.Capr-11-0499 |
0.461 |
|
2012 |
Guntupalli SR, Zighelboim I, Kizer NT, Zhang Q, Powell MA, Thaker PH, Goodfellow PJ, Mutch DG. Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer. Gynecologic Oncology. 124: 31-5. PMID 22030404 DOI: 10.1016/J.Ygyno.2011.09.017 |
0.346 |
|
2012 |
Ioffe YJ, Chiappinelli KB, Mutch DG, Zighelboim I, Goodfellow PJ. Phosphatase and tensin homolog (PTEN) pseudogene expression in endometrial cancer: a conserved regulatory mechanism important in tumorigenesis? Gynecologic Oncology. 124: 340-6. PMID 22005521 DOI: 10.1016/J.Ygyno.2011.10.011 |
0.725 |
|
2012 |
Sundaram V, Xie M, Zhang B, Chiappinelli KB, Goodfellow PJ, Wang T. Abstract LB-379: Transposable elements and the epigenetic control of gene regulation of endometrial cancer Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-379 |
0.69 |
|
2012 |
Huang Y, Rader JS, Stoner GD, Goodfellow PJ, Huang TH. Abstract 4040: Silence of miR-203 by promoter methylation in endometrial cancer Cancer Research. 72: 4040-4040. DOI: 10.1158/1538-7445.Am2012-4040 |
0.413 |
|
2012 |
Chiappinelli KB, Haynes BC, Brent MR, Goodfellow PJ. Abstract 2312: A genomics approach to determining the role of DICER1 in tumorigenesis: Interferon responses in the cancer cell Cancer Research. 72: 2312-2312. DOI: 10.1158/1538-7445.Am2012-2312 |
0.678 |
|
2012 |
Brooks R, Darcy K, Tritchler D, Gold D, Birrer M, Rader J, Kizer N, Thaker P, Mutch D, Goodfellow P. Single nucleotide polymorphisms in IL8RB, EGFR, ABL1, and SPAG9 Are associated with lymph node metastasis in endometrial cancer: A Gynecologic Oncology Group and Washington University School of Medicine study Gynecologic Oncology. 125: S17. DOI: 10.1016/J.Ygyno.2011.12.040 |
0.301 |
|
2011 |
Haiman CA, Chen GK, Vachon CM, Canzian F, Dunning A, Millikan RC, Wang X, Ademuyiwa F, Ahmed S, Ambrosone CB, Baglietto L, Balleine R, Bandera EV, Beckmann MW, Berg CD, ... ... Goodfellow P, et al. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nature Genetics. 43: 1210-4. PMID 22037553 DOI: 10.1038/Ng.985 |
0.326 |
|
2011 |
Link DC, Schuettpelz LG, Shen D, Wang J, Walter MJ, Kulkarni S, Payton JE, Ivanovich J, Goodfellow PJ, Le Beau M, Koboldt DC, Dooling DJ, Fulton RS, Bender RH, Fulton LL, et al. Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. Jama. 305: 1568-76. PMID 21505135 DOI: 10.1001/Jama.2011.473 |
0.469 |
|
2011 |
Zighelboim I, Reinhart AJ, Gao F, Schmidt AP, Mutch DG, Thaker PH, Goodfellow PJ. DICER1 expression and outcomes in endometrioid endometrial adenocarcinoma. Cancer. 117: 1446-53. PMID 21425145 DOI: 10.1002/Cncr.25665 |
0.42 |
|
2011 |
Dewdney SB, Rimel BJ, Thaker PH, Thompson DM, Schmidt A, Huettner P, Mutch DG, Gao F, Goodfellow PJ. Aberrant methylation of the X-linked ribosomal S6 kinase RPS6KA6 (RSK4) in endometrial cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2120-9. PMID 21372219 DOI: 10.1158/1078-0432.Ccr-10-2668 |
0.427 |
|
2011 |
Kizer NT, Gao F, Guntupalli S, Thaker PH, Powell MA, Goodfellow PJ, Mutch DG, Zighelboim I. Lower uterine segment involvement is associated with poor outcomes in early-stage endometrioid endometrial carcinoma. Annals of Surgical Oncology. 18: 1419-24. PMID 21181281 DOI: 10.1245/S10434-010-1454-9 |
0.332 |
|
2011 |
Chiappinelli KB, Haynes BC, Schillebeeckx M, Mitra RD, Brent MR, Goodfellow PJ. Abstract 1173: A genomics approach to understanding DICER1's role in tumorigenesis Cancer Research. 71: 1173-1173. DOI: 10.1158/1538-7445.Am2011-1173 |
0.7 |
|
2011 |
Ludwig S, Ivanovich J, Graubert T, Goodfellow P. P2-07-01: Copy Number Variants in Early-Onset-Breast Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P2-07-01 |
0.408 |
|
2010 |
Ramsingh G, Koboldt DC, Trissal M, Chiappinelli KB, Wylie T, Koul S, Chang LW, Nagarajan R, Fehniger TA, Goodfellow P, Magrini V, Wilson RK, Ding L, Ley TJ, Mardis ER, et al. Complete characterization of the microRNAome in a patient with acute myeloid leukemia. Blood. 116: 5316-26. PMID 20876853 DOI: 10.1182/Blood-2010-05-285395 |
0.684 |
|
2010 |
Chiappinelli KB, Rimel BJ, Massad LS, Goodfellow PJ. Infrequent methylation of the DUSP6 phosphatase in endometrial cancer. Gynecologic Oncology. 119: 146-50. PMID 20638106 DOI: 10.1016/J.Ygyno.2010.06.015 |
0.709 |
|
2010 |
Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, Harris CC, McLellan MD, Fulton RS, Fulton LL, Abbott RM, Hoog J, Dooling DJ, Koboldt DC, Schmidt H, ... ... Goodfellow PJ, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature. 464: 999-1005. PMID 20393555 DOI: 10.1038/Nature08989 |
0.404 |
|
2010 |
Huang YW, Luo J, Weng YI, Mutch DG, Goodfellow PJ, Miller DS, Huang TH. Promoter hypermethylation of CIDEA, HAAO and RXFP3 associated with microsatellite instability in endometrial carcinomas. Gynecologic Oncology. 117: 239-47. PMID 20211485 DOI: 10.1016/J.Ygyno.2010.02.006 |
0.342 |
|
2010 |
Byron SA, Gartside MG, Wellens CL, Goodfellow PJ, Birrer MJ, Campbell IG, Pollock PM. FGFR2 mutations are rare across histologic subtypes of ovarian cancer. Gynecologic Oncology. 117: 125-9. PMID 20106510 DOI: 10.1016/J.Ygyno.2009.12.002 |
0.46 |
|
2010 |
Mei M, Liu D, Dong S, Ingvarsson S, Goodfellow PJ, Chen H. The MLH1 -93 promoter variant influences gene expression. Cancer Epidemiology. 34: 93-5. PMID 20060799 DOI: 10.1016/J.Canep.2009.12.009 |
0.35 |
|
2010 |
Ramsingh G, Koboldt DC, Trissal M, Chiappinelli KB, Wylie T, Koul S, Chang L, Nagarajan R, Fehniger TA, Goodfellow P, Magrini V, Wilson RK, Ding L, Ley TJ, Mardis ER, et al. Abstract B12: Complete characterization of the “microRNAome” of a human acute myeloid leukemia Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcmusa10-B12 |
0.669 |
|
2009 |
Huang YW, Liu JC, Deatherage DE, Luo J, Mutch DG, Goodfellow PJ, Miller DS, Huang TH. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Research. 69: 9038-46. PMID 19887623 DOI: 10.1158/0008-5472.Can-09-1499 |
0.404 |
|
2009 |
Zighelboim I, Powell MA, Babb SA, Whelan AJ, Schmidt AP, Clendenning M, Senter L, Thibodeau SN, de la Chapelle A, Goodfellow PJ. Epitope-positive truncating MLH1 mutation and loss of PMS2: implications for IHC-directed genetic testing for Lynch syndrome. Familial Cancer. 8: 501-4. PMID 19672700 DOI: 10.1007/S10689-009-9276-2 |
0.492 |
|
2009 |
Hill DA, Ivanovich J, Priest JR, Gurnett CA, Dehner LP, Desruisseau D, Jarzembowski JA, Wikenheiser-Brokamp KA, Suarez BK, Whelan AJ, Williams G, Bracamontes D, Messinger Y, Goodfellow PJ. DICER1 mutations in familial pleuropulmonary blastoma. Science (New York, N.Y.). 325: 965. PMID 19556464 DOI: 10.1126/Science.1174334 |
0.441 |
|
2009 |
Varley KE, Mutch DG, Edmonston TB, Goodfellow PJ, Mitra RD. Intra-tumor heterogeneity of MLH1 promoter methylation revealed by deep single molecule bisulfite sequencing. Nucleic Acids Research. 37: 4603-12. PMID 19494183 DOI: 10.1093/Nar/Gkp457 |
0.413 |
|
2009 |
Zighelboim I, Schmidt AP, Gao F, Thaker PH, Powell MA, Rader JS, Gibb RK, Mutch DG, Goodfellow PJ. ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3091-6. PMID 19470935 DOI: 10.1200/Jco.2008.19.9802 |
0.443 |
|
2009 |
Goodfellow PJ. Clinicopathologic significance of DNA mismatch repair defects in endometrial cancer: the devil is in the details. Gynecologic Oncology. 113: 151-2. PMID 19362225 DOI: 10.1016/J.Ygyno.2009.03.013 |
0.362 |
|
2009 |
Rimel BJ, Huettner P, Powell MA, Mutch DG, Goodfellow PJ. Absence of MGMT promoter methylation in endometrial cancer. Gynecologic Oncology. 112: 224-8. PMID 18973931 DOI: 10.1016/J.Ygyno.2008.08.038 |
0.405 |
|
2008 |
Byron SA, Gartside MG, Wellens CL, Mallon MA, Keenan JB, Powell MA, Goodfellow PJ, Pollock PM. Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Research. 68: 6902-7. PMID 18757403 DOI: 10.1158/0008-5472.Can-08-0770 |
0.442 |
|
2008 |
Case AS, Zighelboim I, Mutch DG, Babb SA, Schmidt AP, Whelan AJ, Thibodeau SN, Goodfellow PJ. Clustering of Lynch syndrome malignancies with no evidence for a role of DNA mismatch repair. Gynecologic Oncology. 108: 438-44. PMID 18022218 DOI: 10.1016/J.Ygyno.2007.09.036 |
0.421 |
|
2008 |
Tierney R, Thompson D, Ivanovich J, Khatri A, Goodfellow P. FGFR2 Single-nucleotide Polymorphism and Risk of Early-onset Breast Cancer International Journal of Radiation Oncology*Biology*Physics. 72: S154. DOI: 10.1016/J.Ijrobp.2008.06.489 |
0.313 |
|
2007 |
Pollock PM, Gartside MG, Dejeza LC, Powell MA, Mallon MA, Davies H, Mohammadi M, Futreal PA, Stratton MR, Trent JM, Goodfellow PJ. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene. 26: 7158-62. PMID 17525745 DOI: 10.1038/Sj.Onc.1210529 |
0.4 |
|
2007 |
Zighelboim I, Goodfellow PJ, Gao F, Gibb RK, Powell MA, Rader JS, Mutch DG. Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 2042-8. PMID 17513808 DOI: 10.1200/Jco.2006.08.2107 |
0.367 |
|
2007 |
Zighelboim I, Goodfellow PJ, Schmidt AP, Walls KC, Mallon MA, Mutch DG, Yan PS, Huang TH, Powell MA. Differential methylation hybridization array of endometrial cancers reveals two novel cancer-specific methylation markers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2882-9. PMID 17504987 DOI: 10.1158/1078-0432.Ccr-06-2367 |
0.404 |
|
2007 |
Zighelboim I, Babb S, Gao F, Powell MA, Mutch DG, Goodfellow PJ. Excess of early onset multiple myeloma in endometrial cancer probands and their relatives suggests common susceptibility. Gynecologic Oncology. 105: 390-4. PMID 17336372 DOI: 10.1016/J.Ygyno.2006.12.022 |
0.418 |
|
2007 |
Chen H, Taylor NP, Sotamaa KM, Mutch DG, Powell MA, Schmidt AP, Feng S, Hampel HL, de la Chapelle A, Goodfellow PJ. Evidence for heritable predisposition to epigenetic silencing of MLH1. International Journal of Cancer. Journal International Du Cancer. 120: 1684-8. PMID 17230510 DOI: 10.1002/Ijc.22406 |
0.358 |
|
2007 |
McCourt CK, Mutch DG, Gibb RK, Rader JS, Goodfellow PJ, Trinkaus K, Powell MA. Body mass index: relationship to clinical, pathologic and features of microsatellite instability in endometrial cancer. Gynecologic Oncology. 104: 535-9. PMID 17109938 DOI: 10.1016/J.Ygyno.2006.09.019 |
0.328 |
|
2006 |
Buttin BM, Powell MA, Goodfellow PJ, Lewin SN, Gibb RK, Mutch DG. Increased risk for abnormalities on perioperative colon screening in patients with microsatellite instability-positive endometrial carcinoma. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 16: 1980-6. PMID 17177835 DOI: 10.1111/J.1525-1438.2006.00735.X |
0.413 |
|
2006 |
Yu J, Mallon MA, Zhang W, Freimuth RR, Marsh S, Watson MA, Goodfellow PJ, McLeod HL. DNA repair pathway profiling and microsatellite instability in colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5104-11. PMID 16951227 DOI: 10.1158/1078-0432.Ccr-06-0547 |
0.399 |
|
2006 |
Taylor NP, Powell MA, Gibb RK, Rader JS, Huettner PC, Thibodeau SN, Mutch DG, Goodfellow PJ. MLH3 mutation in endometrial cancer. Cancer Research. 66: 7502-8. PMID 16885347 DOI: 10.1158/0008-5472.Can-06-0248 |
0.509 |
|
2006 |
Taylor NP, Zighelboim I, Huettner PC, Powell MA, Gibb RK, Rader JS, Mutch DG, Edmonston TB, Goodfellow PJ. DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 19: 1333-8. PMID 16810312 DOI: 10.1038/Modpathol.3800654 |
0.325 |
|
2006 |
Kabbarah O, Mallon MA, Pfeifer JD, Goodfellow PJ. Transcriptional profiling endometrial carcinomas microdissected from DES-treated mice identifies changes in gene expression associated with estrogenic tumor promotion. International Journal of Cancer. Journal International Du Cancer. 119: 1843-9. PMID 16804899 DOI: 10.1002/Ijc.22063 |
0.77 |
|
2006 |
Marsh S, Mallon MA, Goodfellow P, McLeod HL. Concordance of pharmacogenetic markers in germline and colorectal tumor DNA. Pharmacogenomics. 6: 873-7. PMID 16296950 DOI: 10.2217/14622416.6.8.873 |
0.408 |
|
2006 |
Taylor NP, Gibb RK, Powell MA, Mutch DG, Huettner PC, Goodfellow PJ. Defective DNA mismatch repair and XRCC2 mutation in uterine carcinosarcomas. Gynecologic Oncology. 100: 107-10. PMID 16169065 DOI: 10.1016/J.Ygyno.2005.07.130 |
0.363 |
|
2005 |
Shin BY, Chen H, Rozek LS, Paxton L, Peel DJ, Anton-Culver H, Rennert G, Mutch DG, Goodfellow PJ, Gruber SB, Lipkin SM. Low allele frequency of MLH1 D132H in American colorectal and endometrial cancer patients. Diseases of the Colon and Rectum. 48: 1723-7. PMID 15991064 DOI: 10.1007/S10350-005-0123-8 |
0.45 |
|
2005 |
Read RD, Goodfellow PJ, Mardis ER, Novak N, Armstrong JR, Cagan RL. A Drosophila model of multiple endocrine neoplasia type 2. Genetics. 171: 1057-81. PMID 15965261 DOI: 10.1534/Genetics.104.038018 |
0.402 |
|
2005 |
Kabbarah O, Sotelo AK, Mallon MA, Winkeler EL, Fan MY, Pfeifer JD, Shibata D, Gutmann DH, Goodfellow PJ. Diethylstilbestrol effects and lymphomagenesis in Mlh1-deficient mice. International Journal of Cancer. Journal International Du Cancer. 115: 666-9. PMID 15700306 DOI: 10.1002/Ijc.20918 |
0.717 |
|
2005 |
Skinner MA, Kalyanaraman S, Safford SD, Heuckeroth RO, Tourtellotte W, Goyeau D, Goodfellow P, Milbrandt JD, Freemerman A. A human yeast artificial chromosome containing the multiple endocrine neoplasia type 2B Ret mutation does not induce medullary thyroid carcinoma but does support the growth of kidneys and partially rescues enteric nervous system development in Ret-deficient mice. The American Journal of Pathology. 166: 265-74. PMID 15632018 DOI: 10.1016/S0002-9440(10)62250-X |
0.312 |
|
2005 |
Li J, Zhang Z, Bidder M, Funk MC, Nguyen L, Goodfellow PJ, Rader JS. IGSF4 promoter methylation and expression silencing in human cervical cancer. Gynecologic Oncology. 96: 150-8. PMID 15589594 DOI: 10.1016/J.Ygyno.2004.08.050 |
0.468 |
|
2005 |
Goodfellow P. MSI in endometrial cancer: Prevalence and clinical applications International Journal of Gynecological Cancer. 15: 402-403. DOI: 10.1111/J.1525-1438.2005.T01-1-Abst_8.X |
0.499 |
|
2004 |
Mutch DG, Powell MA, Mallon MA, Goodfellow PJ. RAS/RAF mutation and defective DNA mismatch repair in endometrial cancers. American Journal of Obstetrics and Gynecology. 190: 935-42. PMID 15118616 DOI: 10.1016/J.Ajog.2004.01.017 |
0.408 |
|
2004 |
Buttin BM, Powell MA, Mutch DG, Babb SA, Huettner PC, Edmonston TB, Herzog TJ, Rader JS, Gibb RK, Whelan AJ, Goodfellow PJ. Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history American Journal of Human Genetics. 74: 1262-1269. PMID 15098177 DOI: 10.1086/421332 |
0.448 |
|
2004 |
Kibel AS, Huagen J, Guo C, Isaacs WB, Yan Y, Pienta KJ, Goodfellow PJ. Expression mapping at 12p12-13 in advanced prostate carcinoma. International Journal of Cancer. 109: 668-72. PMID 14999772 DOI: 10.1002/Ijc.20060 |
0.434 |
|
2004 |
Buttin BM, Powell MA, Mutch DG, Rader JS, Herzog TJ, Gibb RK, Huettner P, Edmonston TB, Goodfellow PJ. Increased risk for hereditary nonpolyposis colorectal cancer-associated synchronous and metachronous malignancies in patients with microsatellite instability-positive endometrial carcinoma lacking MLH1 promoter methylation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 481-90. PMID 14760069 DOI: 10.1158/1078-0432.Ccr-1110-03 |
0.379 |
|
2003 |
Kabbarah O, Mallon MA, Pfeifer JD, Edelmann W, Kucherlapati R, Goodfellow PJ. A panel of repeat markers for detection of microsatellite instability in murine tumors. Molecular Carcinogenesis. 38: 155-9. PMID 14639654 DOI: 10.1002/Mc.10157 |
0.745 |
|
2003 |
Gutmann DH, Winkeler E, Kabbarah O, Hedrick N, Dudley S, Goodfellow PJ, Liskay RM. Mlh1 deficiency accelerates myeloid leukemogenesis in neurofibromatosis 1 (Nf1) heterozygous mice. Oncogene. 22: 4581-5. PMID 12881715 DOI: 10.1038/Sj.Onc.1206768 |
0.692 |
|
2003 |
Goodfellow PJ, Buttin BM, Herzog TJ, Rader JS, Gibb RK, Swisher E, Look K, Walls KC, Fan MY, Mutch DG. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proceedings of the National Academy of Sciences of the United States of America. 100: 5908-13. PMID 12732731 DOI: 10.1073/Pnas.1030231100 |
0.506 |
|
2003 |
Kabbarah O, Pinto K, Mutch DG, Goodfellow PJ. Expression profiling of mouse endometrial cancers microdissected from ethanol-fixed, paraffin-embedded tissues. The American Journal of Pathology. 162: 755-62. PMID 12598310 DOI: 10.1016/S0002-9440(10)63872-2 |
0.744 |
|
2003 |
Noonan FC, Goodfellow PJ, Staloch LJ, Mutch DG, Simon TC. Antisense transcripts at the EMX2 locus in human and mouse. Genomics. 81: 58-66. PMID 12573261 DOI: 10.1016/S0888-7543(02)00023-X |
0.756 |
|
2002 |
Whelan AJ, Babb S, Mutch DG, Rader J, Herzog TJ, Todd C, Ivanovich JL, Goodfellow PJ. MSI in endometrial carcinoma: absence of MLH1 promoter methylation is associated with increased familial risk for cancers. International Journal of Cancer. Journal International Du Cancer. 99: 697-704. PMID 12115503 DOI: 10.1002/Ijc.10429 |
0.459 |
|
2002 |
Horowitz N, Pinto K, Mutch DG, Herzog TJ, Rader JS, Gibb R, Bocker-Edmonston T, Goodfellow PJ. Microsatellite instability, MLH1 promoter methylation, and loss of mismatch repair in endometrial cancer and concomitant atypical hyperplasia. Gynecologic Oncology. 86: 62-8. PMID 12079302 DOI: 10.1006/Gyno.2002.6724 |
0.355 |
|
2001 |
Cohn DE, Mutch DG, Herzog TJ, Rader JS, Dintzis SM, Gersell DJ, Todd CR, Goodfellow PJ. Genotypic and phenotypic progression in endometrial tumorigenesis: determining when defects in DNA mismatch repair and KRAS2 occur. Genes, Chromosomes & Cancer. 32: 295-301. PMID 11746970 DOI: 10.1002/Gcc.1194 |
0.41 |
|
2001 |
Braybrook C, Doudney K, Marçano AC, Arnason A, Bjornsson A, Patton MA, Goodfellow PJ, Moore GE, Stanier P. The T-box transcription factor gene TBX22 is mutated in X-linked cleft palate and ankyloglossia. Nature Genetics. 29: 179-83. PMID 11559848 DOI: 10.1038/Ng730 |
0.353 |
|
2001 |
Noonan FC, Mutch DG, Ann Mallon M, Goodfellow PJ. Characterization of the homeodomain gene EMX2: sequence conservation, expression analysis, and a search for mutations in endometrial cancers. Genomics. 76: 37-44. PMID 11549315 DOI: 10.1006/Geno.2001.6590 |
0.796 |
|
2001 |
Kibel AS, Christopher M, Faith DA, Bova GS, Goodfellow PJ, Isaacs WB. Methylation and mutational analysis of p27(kip1) in prostate carcinoma. The Prostate. 48: 248-53. PMID 11536304 DOI: 10.1002/Pros.1104 |
0.369 |
|
2001 |
Cohn D, Mutch D, Elbendary A, Rader J, Herzog T, Goodfellow P. No evidence for BCL10 mutation in endometrial cancers with microsatellite instability. Human Mutation. 17: 117-21. PMID 11180594 DOI: 10.1002/1098-1004(200102)17:2<117::Aid-Humu3>3.0.Co;2-D |
0.491 |
|
2000 |
Cohn DE, Basil JB, Venegoni AR, Mutch DG, Rader JS, Herzog TJ, Gersell DJ, Goodfellow PJ. Absence of PTEN repeat tract mutation in endometrial cancers with microsatellite instability. Gynecologic Oncology. 79: 101-6. PMID 11006040 DOI: 10.1006/Gyno.2000.5900 |
0.488 |
|
2000 |
Mason JE, Goodfellow PJ, Grundy PE, Skinner MA. 16q loss of heterozygosity and microsatellite instability in Wilms' tumor. Journal of Pediatric Surgery. 35: 891-6; discussion 89. PMID 10873032 DOI: 10.1053/Jpsu.2000.6911 |
0.364 |
|
2000 |
Cohn DE, Babb S, Whelan AJ, Mutch DG, Herzog TJ, Rader JS, Elbendary A, Goodfellow PJ. Atypical clustering of gynecologic malignancies: A family study including molecular analysis of candidate genes. Gynecologic Oncology. 77: 18-25. PMID 10739686 DOI: 10.1006/Gyno.1999.5709 |
0.394 |
|
1999 |
Basil JB, Swisher EM, Herzog TJ, Rader JS, Elbendary A, Mutch DG, Goodfellow PJ. Mutational analysis of the PMS2 gene in sporadic endometrial cancers with microsatellite instability. Gynecologic Oncology. 74: 395-9. PMID 10479499 DOI: 10.1006/Gyno.1999.5486 |
0.453 |
|
1999 |
Arlt MF, Li M, Herzog TJ, Goodfellow PJ. A 1-Mb bacterial clone contig spanning the endometrial cancer deletion region at 1p32-p33. Genomics. 57: 62-9. PMID 10191084 DOI: 10.1006/Geno.1999.5652 |
0.369 |
|
1999 |
Mutch MG, Dilley WG, Sanjurjo F, DeBenedetti MK, Doherty GM, Wells SA, Goodfellow PJ, Lairmore TC. Germline mutations in the multiple endocrine neoplasia type 1 gene: evidence for frequent splicing defects. Human Mutation. 13: 175-85. PMID 10090472 DOI: 10.1002/(Sici)1098-1004(1999)13:3<175::Aid-Humu1>3.0.Co;2-R |
0.389 |
|
1999 |
Herfarth KK, Brent TP, Danam RP, Remack JS, Kodner IJ, Wells SA, Goodfellow PJ. A specific CpG methylation pattern of the MGMT promoter region associated with reduced MGMT expression in primary colorectal cancers. Molecular Carcinogenesis. 24: 90-8. PMID 10078936 DOI: 10.1002/(Sici)1098-2744(199902)24:2<90::Aid-Mc3>3.0.Co;2-B |
0.415 |
|
1999 |
Simpkins SB, Bocker T, Swisher EM, Mutch DG, Gersell DJ, Kovatich AJ, Palazzo JP, Fishel R, Goodfellow PJ. MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers Human Molecular Genetics. 8: 661-666. PMID 10072435 DOI: 10.1093/Hmg/8.4.661 |
0.524 |
|
1999 |
Swisher EM, Peiffer-Schneider S, Mutch DG, Herzog TJ, Rader JS, Elbendary A, Goodfellow PJ. Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability. Cancer. 85: 119-26. PMID 9921983 DOI: 10.1002/(Sici)1097-0142(19990101)85:1<119::Aid-Cncr17>3.0.Co;2-5 |
0.406 |
|
1999 |
Simpkins SB, Peiffer-Schneider S, Mutch DG, Gersell D, Goodfellow PJ. PTEN mutations in endometrial cancers with 10q LOH: additional evidence for the involvement of multiple tumor suppressors. Gynecologic Oncology. 71: 391-5. PMID 9887237 DOI: 10.1006/Gyno.1998.5208 |
0.434 |
|
1998 |
Klaus K, Herfarth F, Ogunbiyi OA, Moley JF, Kodner IJ, Wells SA, Goodfellow PJ. Four new mutations in the DNA mismatch repair gene MLH1 in colorectal cancers with microsatellite instability. Mutations in brief no. 157. Online. Human Mutation. 12: 73. PMID 10627141 DOI: 10.1002/(Sici)1098-1004(1998)12:1<73::Aid-Humu20>3.0.Co;2-F |
0.439 |
|
1998 |
Peiffer-Schneider S, Noonan FC, Mutch DG, Simpkins SB, Herzog T, Rader J, Elbendary A, Gersell DJ, Call K, Goodfellow PJ. Mapping an endometrial cancer tumor suppressor gene at 10q25 and development of a bacterial clone contig for the consensus deletion interval. Genomics. 52: 9-16. PMID 9740666 DOI: 10.1006/Geno.1998.5399 |
0.771 |
|
1998 |
Ogunbiyi OA, Goodfellow PJ, Herfarth K, Gagliardi G, Swanson PE, Birnbaum EH, Read TE, Fleshman JW, Kodner IJ, Moley JF. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 427-33. PMID 9469325 DOI: 10.1200/Jco.1998.16.2.427 |
0.407 |
|
1998 |
Swisher EM, Mutch DG, Herzog TJ, Rader JS, Kowalski LD, Elbendary A, Goodfellow PJ. Analysis of MSH3 in Endometrial Cancers With Defective DNA Mismatch Repair Journal of the Society For Gynecologic Investigation. 5: 210-216. DOI: 10.1016/S1071-5576(98)00016-1 |
0.488 |
|
1997 |
Ogunbiyi OA, Goodfellow PJ, Gagliardi G, Swanson PE, Birnbaum EH, Fleshman JW, Kodner IJ, Moley JF. Prognostic value of chromosome 1p allelic loss in colon cancer. Gastroenterology. 113: 761-6. PMID 9287966 DOI: 10.1016/S0016-5085(97)70169-0 |
0.43 |
|
1997 |
Kitamura Y, Goodfellow PJ, Shimizu K, Nagahama M, Ito K, Kitagawa W, Akasu H, Takami H, Tanaka S, Wells SA. Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC. Oncogene. 14: 3103-6. PMID 9223675 DOI: 10.1038/Sj.Onc.1201102 |
0.363 |
|
1997 |
Musholt TJ, Goodfellow PJ, Scheumann GF, Pichlmayr R, Wells SA, Moley JF. Differential display in primary and metastatic medullary thyroid carcinoma. The Journal of Surgical Research. 69: 94-100. PMID 9202653 DOI: 10.1006/Jsre.1997.5038 |
0.408 |
|
1997 |
Tung WS, Shevlin DW, Kaleem Z, Tribune DJ, Wells SA, Goodfellow PJ. Allelotype of follicular thyroid carcinomas reveals genetic instability consistent with frequent nondisjunctional chromosomal loss. Genes, Chromosomes & Cancer. 19: 43-51. PMID 9135994 DOI: 10.1002/(Sici)1098-2264(199705)19:1<43::Aid-Gcc7>3.0.Co;2-0 |
0.404 |
|
1997 |
Kowalski LD, Mutch DG, Herzog TJ, Rader JS, Goodfellow PJ. Mutational analysis of MLH1 and MSH2 in 25 prospectively-acquired RER+ endometrial cancers. Genes, Chromosomes & Cancer. 18: 219-27. PMID 9071575 DOI: 10.1002/(Sici)1098-2264(199703)18:3<219::Aid-Gcc8>3.0.Co;2-4 |
0.475 |
|
1997 |
Herfarth KK, Kodner IJ, Whelan AJ, Ivanovich JL, Bracamontes JR, Wells SA, Goodfellow PJ. Mutations in MLH1 are more frequent than in MSH2 in sporadic colorectal cancers with microsatellite instability. Genes, Chromosomes & Cancer. 18: 42-9. PMID 8993979 DOI: 10.1002/(Sici)1098-2264(199701)18:1<42::Aid-Gcc5>3.0.Co;2-1 |
0.478 |
|
1997 |
Arlt MF, Herzog TJ, Mutch DG, Gersell DJ, Liu H, Goodfellow PJ. Frequent deletion of chromosome 1p sequences in an aggressive histologic subtype of endometrial cancer. Human Molecular Genetics. 5: 1017-21. PMID 8817340 DOI: 10.1093/Hmg/5.7.1017 |
0.46 |
|
1996 |
Arlt MF, Goodfellow PJ, Rottman JN. Short Communication: Dinucleotide Repeat in the third Intron of the Fabp3Imdgi Putative Tumor Suppressor Gene Disease Markers. 13: 57-59. PMID 8875119 DOI: 10.1155/1996/607063 |
0.417 |
|
1996 |
Arlt MF, Herzog TJ, Mutch DG, Goodfellow PJ. Loss of heterozygosity of chromosome 3p sequences is an infrequent event in endometrial cancer. Gynecologic Oncology. 60: 308-12. PMID 8631557 DOI: 10.1006/Gyno.1996.0044 |
0.425 |
|
1996 |
Bartsch D, Shevlin DW, Callery MP, Norton JA, Wells SA, Goodfellow PJ. Reduced survival in patients with ductal pancreatic adenocarcinoma associated with CDKN2 mutation. Journal of the National Cancer Institute. 88: 680-2. PMID 8627645 DOI: 10.1093/Jnci/88.10.680 |
0.305 |
|
1996 |
Bartsch D, Peiffer SL, Kaleem Z, Wells SA, Goodfellow PJ. Mxi1 tumor suppressor gene is not mutated in primary pancreatic adenocarcinoma. Cancer Letters. 102: 73-6. PMID 8603382 DOI: 10.1016/0304-3835(96)04167-5 |
0.445 |
|
1996 |
Tung WS, Shevlin DW, Bartsch D, Norton JA, Wells SA, Goodfellow PJ. Infrequent CDKN2 mutation in human differentiated thyroid cancers. Molecular Carcinogenesis. 15: 5-10. PMID 8561866 DOI: 10.1002/(Sici)1098-2744(199601)15:1<5::Aid-Mc2>3.0.Co;2-K |
0.529 |
|
1995 |
Bartsch D, Shevlin DW, Tung WS, Kisker O, Wells SA, Goodfellow PJ. Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas. Genes, Chromosomes & Cancer. 14: 189-95. PMID 8589035 DOI: 10.1002/Gcc.2870140306 |
0.445 |
|
1995 |
Whelan AJ, Bartsch D, Goodfellow PJ. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. The New England Journal of Medicine. 333: 975-7. PMID 7666917 DOI: 10.1056/Nejm199510123331505 |
0.496 |
|
1995 |
Peiffer SL, Bartsch D, Whelan AJ, Mutch DG, Herzog TJ, Goodfellow PJ. Low frequency of CDKN2 mutation in endometrial carcinomas. Molecular Carcinogenesis. 13: 210-2. PMID 7646759 DOI: 10.1002/Mc.2940130403 |
0.411 |
|
1995 |
Goodfellow PJ, Wells SA. RET gene and its implications for cancer. Journal of the National Cancer Institute. 87: 1515-23. PMID 7563185 DOI: 10.1093/Jnci/87.20.1515 |
0.396 |
|
1995 |
Gagliardi G, Kodner I, Goodfellow P, Moley J. LOH of chromosome 1P is associated with decreased five year survival in colon cancer Gastroenterology. 108: A472. DOI: 10.1016/0016-5085(95)26201-6 |
0.354 |
|
1994 |
Goodfellow PJ. Inherited cancers associated with the RET proto-oncogene. Current Opinion in Genetics & Development. 4: 446-52. PMID 7919923 DOI: 10.1016/0959-437X(94)90034-5 |
0.438 |
|
1994 |
Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, Wells SA, Goodfellow PJ, Donis-Keller H. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proceedings of the National Academy of Sciences of the United States of America. 91: 1579-83. PMID 7906417 DOI: 10.1073/Pnas.91.4.1579 |
0.329 |
|
1993 |
Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Human Molecular Genetics. 2: 851-6. PMID 8103403 DOI: 10.1093/Hmg/2.7.851 |
0.355 |
|
1993 |
Brooks-Wilson AR, Lichter JB, Ward DC, Kidd KK, Goodfellow PJ. Genomic and yeast artificial chromosome long-range physical maps linking six loci in 10q11.2 and spanning the multiple endocrine neoplasia type 2A (MEN2A) region. Genomics. 17: 611-7. PMID 7902324 DOI: 10.1006/Geno.1993.1380 |
0.359 |
|
1988 |
Spurr NK, Gough A, Goodfellow PJ, Goodfellow PN, Lee MG, Nurse P. Evolutionary conservation of the human homologue of the yeast cell cycle control gene cdc2 and assignment of Cd2 to chromosome 10. Human Genetics. 78: 333-7. PMID 2896153 DOI: 10.1007/Bf00291730 |
0.323 |
|
1987 |
Simpson NE, Kidd KK, Goodfellow PJ, McDermid H, Myers S, Kidd JR, Jackson CE, Duncan AM, Farrer LA, Brasch K. Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage. Nature. 328: 528-30. PMID 2886918 DOI: 10.1038/328528A0 |
0.32 |
|
1987 |
Pritchard CA, Goodfellow PJ, Goodfellow PN. Mapping the limits of the human pseudoautosomal region and a candidate sequence for the male-determining gene. Nature. 328: 273-5. PMID 2885758 DOI: 10.1038/328273A0 |
0.306 |
|
Show low-probability matches. |